Overview

Phase 2 Study of T-DXd in the Neoadjuvant Treatment for Patients With HER2 Positive Gastric and GEJ Adenocarcinoma

Status:
Not yet recruiting

Trial end date:
2025-03-31

Target enrollment:

Participant gender:

Summary

This study is an open-label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of neoadjuvant chemotherapy with T-DXd monotherapy in patients with HER2-positive gastric cancer.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Center Hospital East

Collaborator:

Daiichi Sankyo Co., Ltd.

Treatments:

Trastuzumab